Team:Brasil-SP/TheIssue/OurSolution

Several studies support Cystatin C as the best biomarker of renal dysfunction when compared to classical biomarkers (urea nitrogen and serum creatinine), because Cystatin C is very sensitive to changes in GFR. However, the available methods to evaluate the levels of Cystatin C are often very expensive and inefficient, such as the immunofluorescence method. Our solution to this problem is to develop a genetic circuit with the ability to detect different levels of Cystatin C in the blood. When the detectable levels of Cystatin C are higher than the normal, it will lead us to diagnose CKD and other renal dysfunctions in early stages. The genetic circuit is shown in the Figure below and the input information is based on Cystatin C inhibitory activity against cysteine proteases, in this case, cathepsin S.